Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 19-20/2019

30.08.2019 | review article

Association of sprue-like enteropathy and angiotensin receptor-1 antagonists

verfasst von: M.D. Univ.-Doz. Dr. René R. Wenzel, Univ.-Prof. Dr. Christian Datz

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 19-20/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Over the past 5 years several case reports and cohort studies have been published that describe a sprue-like enteropathy (SLE) with abdominal pain, chronic diarrhea and weight loss, after taking angiotensin type 1 receptor blockers (ARB). The initial case series from the Mayo Clinic, which described 22 cases of olmesartan-induced SLE, was followed by numerous case descriptions for almost all ARBs. A total of 73 case reports have been described so far that show evidence of ARB-associated enteropathy with villous atrophy and full recovery 3–12 months after discontinuation of the sartan in question. Of these, 59 cases were olmesartan-associated cases of SLE, another 14 case reports have been published for telmisartan (4), valsartan (3), losartan (2), candesartan (1) and eprosartan (1). Based on the available cohort studies, ARB-associated intestinal malabsorption occurs in 9.8–14 cases per 100,000 patients treated with ARBs, the number treated to harm is over 31,000 patient-years. Although the majority of case reports have been published with olmesartan, in the cohort studies no clear difference within the ARBs can be ruled out. The SLE is rare but must be suspected and diagnostically investigated in every patient presenting with abdominal discomfort, chronic diarrhea and weight loss who is being treated with an ARB, after other causes have been ruled out. In such cases, discontinuing the ARB leads to a full recovery.
Literatur
1.
Zurück zum Zitat Freeman HJ. Drug-induced Sprue-like intestinal disease. Int J Celiac Dis. 2014;2:49–53. CrossRef Freeman HJ. Drug-induced Sprue-like intestinal disease. Int J Celiac Dis. 2014;2:49–53. CrossRef
2.
Zurück zum Zitat Adike A, Corral J, Rybnicek D, Sussman D, Shah S, Quigley E. Olmesartan-induced Enteropathy. Methodist Debakey Cardiovasc J. 2016;12:230–2. CrossRefPubMedPubMedCentral Adike A, Corral J, Rybnicek D, Sussman D, Shah S, Quigley E. Olmesartan-induced Enteropathy. Methodist Debakey Cardiovasc J. 2016;12:230–2. CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Scialom S, Malamut G, Meresse B, et al. Gastrointestinal disorder associated with Olmesartan mimics Autoimmune Enteropathy. PLoS ONE. 2015;10:e125024. CrossRefPubMedPubMedCentral Scialom S, Malamut G, Meresse B, et al. Gastrointestinal disorder associated with Olmesartan mimics Autoimmune Enteropathy. PLoS ONE. 2015;10:e125024. CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Ianiro G, Bibbo S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40:16–23. CrossRefPubMed Ianiro G, Bibbo S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40:16–23. CrossRefPubMed
5.
6.
Zurück zum Zitat Fiorucci G, Puxeddu E, Colella R, Reboldi PG, Villanacci V, Bassotti G. Severe spruelike enteropathy due to olmesartan. Rev Esp Enferm Dig. 2014;106:142–4. CrossRefPubMed Fiorucci G, Puxeddu E, Colella R, Reboldi PG, Villanacci V, Bassotti G. Severe spruelike enteropathy due to olmesartan. Rev Esp Enferm Dig. 2014;106:142–4. CrossRefPubMed
7.
Zurück zum Zitat DeGaetani M, Tennyson CA, Lebwohl B, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108:647–53. CrossRefPubMed DeGaetani M, Tennyson CA, Lebwohl B, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108:647–53. CrossRefPubMed
8.
Zurück zum Zitat Dreifuss SE, Tomizawa Y, Farber NJ, Davison JM, Sohnen AE. Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Rep Gastrointest Med. 2013;2013:1–3. Dreifuss SE, Tomizawa Y, Farber NJ, Davison JM, Sohnen AE. Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Rep Gastrointest Med. 2013;2013:1–3.
9.
Zurück zum Zitat Fabian E, Schiller D, Wenzl H, et al. Clinical-Pathological Conference Series from the Medical University of Graz: Case No 156: 82-year-old woman with chronic diarrhea and weight loss of 20 kilograms. Wien Klin Wochenschr. 2015;127:974–80. CrossRefPubMedPubMedCentral Fabian E, Schiller D, Wenzl H, et al. Clinical-Pathological Conference Series from the Medical University of Graz: Case No 156: 82-year-old woman with chronic diarrhea and weight loss of 20 kilograms. Wien Klin Wochenschr. 2015;127:974–80. CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Basson M, Mezzarobba M, Weill A, et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut. 2016;65:1664–9. CrossRefPubMed Basson M, Mezzarobba M, Weill A, et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut. 2016;65:1664–9. CrossRefPubMed
11.
Zurück zum Zitat Marthey L, Cadiot G, Seksik P, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40:1103–9. CrossRefPubMed Marthey L, Cadiot G, Seksik P, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40:1103–9. CrossRefPubMed
12.
Zurück zum Zitat Mondet L, Pierson-Marchandise M, Gras V, et al. Angiotensin II receptor blockers-induced enteropathy: not just olmesartan! A case report with candesartan. Fundam Clin Pharmacol. 2016;30:62. Mondet L, Pierson-Marchandise M, Gras V, et al. Angiotensin II receptor blockers-induced enteropathy: not just olmesartan! A case report with candesartan. Fundam Clin Pharmacol. 2016;30:62.
13.
Zurück zum Zitat Maier H, Hehemann K, Vieth M. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan. Cesk Patol. 2015;51:87–8. PubMed Maier H, Hehemann K, Vieth M. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan. Cesk Patol. 2015;51:87–8. PubMed
14.
Zurück zum Zitat Cammarota G, Ianiro G, Bibbo S, Letter GA. telmisartan associated enteropathy—is there any class effect? Authors’ reply. Aliment Pharmacol Ther. 2014;40:570. CrossRefPubMed Cammarota G, Ianiro G, Bibbo S, Letter GA. telmisartan associated enteropathy—is there any class effect? Authors’ reply. Aliment Pharmacol Ther. 2014;40:570. CrossRefPubMed
15.
Zurück zum Zitat Negro A, Rossi GM, Santi R, Iori V, De Marco L. A case of severe Sprue-like Enteropathy associated with Losartan. J Clin Gastroenterol. 2015;49:794. CrossRefPubMed Negro A, Rossi GM, Santi R, Iori V, De Marco L. A case of severe Sprue-like Enteropathy associated with Losartan. J Clin Gastroenterol. 2015;49:794. CrossRefPubMed
16.
Zurück zum Zitat Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A case of severe Sprue-like Enteropathy associated with Valsartan. Acg Case Rep J. 2015;2:92–4. CrossRefPubMedPubMedCentral Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A case of severe Sprue-like Enteropathy associated with Valsartan. Acg Case Rep J. 2015;2:92–4. CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Sawant AP, Spoletini G, Etherington C. Losartan-associated spruelike enteropathy in a post-lung transplant cystic fibrosis patient. J Cyst Fibros. 2017;16:135. CrossRef Sawant AP, Spoletini G, Etherington C. Losartan-associated spruelike enteropathy in a post-lung transplant cystic fibrosis patient. J Cyst Fibros. 2017;16:135. CrossRef
18.
Zurück zum Zitat Cyrany J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova M. Letter: telmisartan-associated enteropathy—is there any class effect? Aliment Pharmacol Ther. 2014;40:569–70. CrossRefPubMed Cyrany J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova M. Letter: telmisartan-associated enteropathy—is there any class effect? Aliment Pharmacol Ther. 2014;40:569–70. CrossRefPubMed
19.
Zurück zum Zitat Mandavdhare HS, Sharma V, Prasad KK, Kumar A, Rathi M, Rana SS. Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers. Intest Res. 2017;15:419–21. CrossRefPubMedPubMedCentral Mandavdhare HS, Sharma V, Prasad KK, Kumar A, Rathi M, Rana SS. Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers. Intest Res. 2017;15:419–21. CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Levens NR. Control of intestinal absorption by the renin-angiotensin system. Am J Physiol. 1985;249:G3–15. CrossRefPubMed Levens NR. Control of intestinal absorption by the renin-angiotensin system. Am J Physiol. 1985;249:G3–15. CrossRefPubMed
24.
Zurück zum Zitat Fandriks L. The renin-angiotensin system and the gastrointestinal mucosa. Acta Physiol (oxf). 2011;201:157–67. CrossRef Fandriks L. The renin-angiotensin system and the gastrointestinal mucosa. Acta Physiol (oxf). 2011;201:157–67. CrossRef
25.
Zurück zum Zitat Fandriks L. The angiotensin II type 2 receptor and the gastrointestinal tract. J Renin Angiotensin Aldosterone Syst. 2010;11:43–8. CrossRefPubMed Fandriks L. The angiotensin II type 2 receptor and the gastrointestinal tract. J Renin Angiotensin Aldosterone Syst. 2010;11:43–8. CrossRefPubMed
26.
Zurück zum Zitat Hallersund P, Elfvin A, Helander HF, Fandriks L. The expression of renin-angiotensin system components in the human gastric mucosa. J Renin Angiotensin Aldosterone Syst. 2011;12:54–64. CrossRefPubMed Hallersund P, Elfvin A, Helander HF, Fandriks L. The expression of renin-angiotensin system components in the human gastric mucosa. J Renin Angiotensin Aldosterone Syst. 2011;12:54–64. CrossRefPubMed
27.
Zurück zum Zitat Hallersund P, Helander HF, Casselbrant A, Edebo A, Fandriks L, Elfvin A. Angiotensin II receptor expression and relation to Helicobacter pylori-infection in the stomach of the Mongolian gerbil. Bmc Gastroenterol. 2010;10:3. CrossRefPubMedPubMedCentral Hallersund P, Helander HF, Casselbrant A, Edebo A, Fandriks L, Elfvin A. Angiotensin II receptor expression and relation to Helicobacter pylori-infection in the stomach of the Mongolian gerbil. Bmc Gastroenterol. 2010;10:3. CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Marietta EV, Nadeau AM, Cartee AK, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther. 2015;42:1303–14. CrossRefPubMedPubMedCentral Marietta EV, Nadeau AM, Cartee AK, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther. 2015;42:1303–14. CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Esteve M, Temino R, Carrasco A, et al. Potential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: a population-based study. Dig Liver Dis. 2016;48:154–61. CrossRefPubMed Esteve M, Temino R, Carrasco A, et al. Potential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: a population-based study. Dig Liver Dis. 2016;48:154–61. CrossRefPubMed
30.
Zurück zum Zitat Ebrahim VS, Martin J, Murthy S, Odstrcil E, Huang H, Polter D. Olmesartan-associated enteropathy. Proc (bayl Univ Med Cent). 2017;30:348–50. CrossRef Ebrahim VS, Martin J, Murthy S, Odstrcil E, Huang H, Polter D. Olmesartan-associated enteropathy. Proc (bayl Univ Med Cent). 2017;30:348–50. CrossRef
31.
Zurück zum Zitat Burbure N, Lebwohl B, Arguelles-Grande C, Green PH, Bhagat G, Lagana S. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127–34. CrossRefPubMed Burbure N, Lebwohl B, Arguelles-Grande C, Green PH, Bhagat G, Lagana S. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127–34. CrossRefPubMed
32.
Zurück zum Zitat Sun L, Wang W, Xiao W, Liang H, Yang Y, Yang H. Angiotensin II induces apoptosis in intestinal epithelial cells through the AT2 receptor, GATA‑6 and the Bax pathway. Biochem Biophys Res Commun. 2012;424:663–8. CrossRefPubMed Sun L, Wang W, Xiao W, Liang H, Yang Y, Yang H. Angiotensin II induces apoptosis in intestinal epithelial cells through the AT2 receptor, GATA‑6 and the Bax pathway. Biochem Biophys Res Commun. 2012;424:663–8. CrossRefPubMed
34.
Zurück zum Zitat Locascio EJ, Mahler SA, Arnold TC. Intestinal angioedema misdiagnosed as recurrent episodes of gastroenteritis. West J Emerg Med. 2010;11:391–4. PubMedPubMedCentral Locascio EJ, Mahler SA, Arnold TC. Intestinal angioedema misdiagnosed as recurrent episodes of gastroenteritis. West J Emerg Med. 2010;11:391–4. PubMedPubMedCentral
35.
Zurück zum Zitat Talbot GH. Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan. Mayo Clin Proc. 2012;87:1231–2. author reply 2. CrossRefPubMedPubMedCentral Talbot GH. Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan. Mayo Clin Proc. 2012;87:1231–2. author reply 2. CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Cartee AK, Genere RJP, Oxentenko AS. New onset villous atrophy in a patient with celiac disease. Baillieres Clin Gastroenterol. 2018;155:988–9. Cartee AK, Genere RJP, Oxentenko AS. New onset villous atrophy in a patient with celiac disease. Baillieres Clin Gastroenterol. 2018;155:988–9.
37.
38.
Zurück zum Zitat Theophile H, David XR, Miremont-Salame G, Haramburu F. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig Liver Dis. 2014;46:465–9. CrossRefPubMed Theophile H, David XR, Miremont-Salame G, Haramburu F. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig Liver Dis. 2014;46:465–9. CrossRefPubMed
39.
Zurück zum Zitat Eusebio M, Caldeira P, Antunes AG, et al. Olmesartan-induced Enteropathy: an unusual cause of villous atrophy. Ge Portuguese J Gastroenterol. 2016;23:91–5. CrossRef Eusebio M, Caldeira P, Antunes AG, et al. Olmesartan-induced Enteropathy: an unusual cause of villous atrophy. Ge Portuguese J Gastroenterol. 2016;23:91–5. CrossRef
40.
Zurück zum Zitat Basson M, et al. Gut. 2015;0:1–6. Basson M, et al. Gut. 2015;0:1–6.
42.
Zurück zum Zitat Marild K, Lebwohl B, Green PH, Murray JA, Ludvigsson JF. Blockers of Angiotensin other than Olmesartan in patients with villous atrophy: a nationwide case-control study. Mayo Clin Proc. 2015;90:730–7. CrossRefPubMed Marild K, Lebwohl B, Green PH, Murray JA, Ludvigsson JF. Blockers of Angiotensin other than Olmesartan in patients with villous atrophy: a nationwide case-control study. Mayo Clin Proc. 2015;90:730–7. CrossRefPubMed
43.
Zurück zum Zitat Mondet L, Pierson-Marchandise, Gras V, Sevester H, Lawson P, Andrejak M, Masmoudi K. Angiotensin II receptor blcokers-induced enteropathy: not just olmesartan! A case report with candesartan. Fund Clin Pharmacol. 2016;30:67 Mondet L, Pierson-Marchandise, Gras V, Sevester H, Lawson P, Andrejak M, Masmoudi K. Angiotensin II receptor blcokers-induced enteropathy: not just olmesartan! A case report with candesartan. Fund Clin Pharmacol. 2016;30:67
44.
Zurück zum Zitat Famularo G, Minisola G. Relapsing Olmesartan-Associated Ileitis. Ann Pharmacother. 2016;50:1070. CrossRefPubMed Famularo G, Minisola G. Relapsing Olmesartan-Associated Ileitis. Ann Pharmacother. 2016;50:1070. CrossRefPubMed
45.
Zurück zum Zitat van Gils T, Robijn RJ, Bouma G, Neefjes-Borst EA, Mulder CJJ. A pitfall in suspected (refractory) celiac disease: Losartan-induced Enteropathy. Am J Gastroenterol. 2017;112:1754–5. CrossRefPubMed van Gils T, Robijn RJ, Bouma G, Neefjes-Borst EA, Mulder CJJ. A pitfall in suspected (refractory) celiac disease: Losartan-induced Enteropathy. Am J Gastroenterol. 2017;112:1754–5. CrossRefPubMed
46.
Zurück zum Zitat Negro A, De Marco L, Cesario V, Santi R, Boni MC, Zanelli M. A case of moderate Sprue-like Enteropathy associated with Telmisartan. J Clin Med Res. 2017;9:1022–5. CrossRefPubMedPubMedCentral Negro A, De Marco L, Cesario V, Santi R, Boni MC, Zanelli M. A case of moderate Sprue-like Enteropathy associated with Telmisartan. J Clin Med Res. 2017;9:1022–5. CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Zanelli M, Negro A, Santi R, et al. Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan. Aliment Pharmacol Ther. 2017;46:471–3. CrossRefPubMed Zanelli M, Negro A, Santi R, et al. Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan. Aliment Pharmacol Ther. 2017;46:471–3. CrossRefPubMed
48.
Zurück zum Zitat Dong YH, Jin Y, Tsacogianis TN, He M, Hsieh PH, Gagne JJ. Use of olmesartan and enteropathy outcomes: a multi-database study. Aliment Pharmacol Ther. 2018;47:792–800. CrossRefPubMed Dong YH, Jin Y, Tsacogianis TN, He M, Hsieh PH, Gagne JJ. Use of olmesartan and enteropathy outcomes: a multi-database study. Aliment Pharmacol Ther. 2018;47:792–800. CrossRefPubMed
49.
Zurück zum Zitat Greywoode R, Braunstein ED, Arguelles-Grande C, Green PH, Lebwohl B. Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study. Mayo Clin Proc. 2014;89:1239–43. CrossRefPubMed Greywoode R, Braunstein ED, Arguelles-Grande C, Green PH, Lebwohl B. Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study. Mayo Clin Proc. 2014;89:1239–43. CrossRefPubMed
50.
Zurück zum Zitat Kamal A, Fain C, Park A, et al. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep (oxf). 2019;7:162–7. CrossRef Kamal A, Fain C, Park A, et al. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep (oxf). 2019;7:162–7. CrossRef
51.
Zurück zum Zitat Mondet I, Pierson-Marchandise M, Gras V, H. S, Lawsan P. Angiotensin II receptor blockers-induced enteropathy: not just olmesartan! Fundam Clin Pharmacol. 2016;30:47–62. Mondet I, Pierson-Marchandise M, Gras V, H. S, Lawsan P. Angiotensin II receptor blockers-induced enteropathy: not just olmesartan! Fundam Clin Pharmacol. 2016;30:47–62.
52.
Zurück zum Zitat Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72. CrossRefPubMed Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72. CrossRefPubMed
53.
Zurück zum Zitat Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–78. CrossRef Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–78. CrossRef
54.
Zurück zum Zitat Bogdarina I, Welham S, King PJ, Burns SP, Clark AJ. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res. 2007;100:520–6. CrossRefPubMedPubMedCentral Bogdarina I, Welham S, King PJ, Burns SP, Clark AJ. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res. 2007;100:520–6. CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Warrington R, Watson W, Kim HL, Antonetti FR. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):1. CrossRef Warrington R, Watson W, Kim HL, Antonetti FR. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):1. CrossRef
56.
Zurück zum Zitat Cummins AG, Roberts-Thomson IC. Prevalence of celiac disease in the Asia-Pacific region. J Gastroenterol Hepatol. 2009;24:1347–51. CrossRefPubMed Cummins AG, Roberts-Thomson IC. Prevalence of celiac disease in the Asia-Pacific region. J Gastroenterol Hepatol. 2009;24:1347–51. CrossRefPubMed
Metadaten
Titel
Association of sprue-like enteropathy and angiotensin receptor-1 antagonists
verfasst von
M.D. Univ.-Doz. Dr. René R. Wenzel
Univ.-Prof. Dr. Christian Datz
Publikationsdatum
30.08.2019
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 19-20/2019
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-019-01539-2

Weitere Artikel der Ausgabe 19-20/2019

Wiener klinische Wochenschrift 19-20/2019 Zur Ausgabe

MUW researcher of the month

MUW researcher of the month

MUW researcher of the month

MUW researcher of the month

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungstipps